{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:20:28Z","timestamp":1790716828640,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012802","name":"Harvard University MIT Phillip T and Susan M Ragon Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012802","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.smim.2021.101475","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T18:18:49Z","timestamp":1618337929000},"page":"101475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Broadly neutralizing antibodies for HIV-1 prevention and therapy"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-9626","authenticated-orcid":false,"given":"Boris","family":"Julg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2021.101475_bib0005","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/CMR.13.4.602","article-title":"Passive immunity in prevention and treatment of infectious diseases","volume":"13","author":"Keller","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.smim.2021.101475_bib0010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/infdis\/165.2.364","article-title":"Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma","volume":"165","author":"Vittecoq","year":"1992","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2021.101475_bib0015","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jac\/dkh428","article-title":"Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10\/2F5\/2G12","volume":"54","author":"Armbruster","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.smim.2021.101475_bib0020","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00002030-200201250-00012","article-title":"A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1","volume":"16","author":"Armbruster","year":"2002","journal-title":"Aids"},{"key":"10.1016\/j.smim.2021.101475_bib0025","doi-asserted-by":"crossref","first-page":"11016","DOI":"10.1128\/JVI.01340-07","article-title":"Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection","volume":"81","author":"Mehandru","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0030","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nm1244","article-title":"Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies","volume":"11","author":"Trkola","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0035","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0040","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1126\/science.280.5371.1949","article-title":"A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding","volume":"280","author":"Rizzuto","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.smim.2021.101475_bib0045","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1086\/516508","article-title":"Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection","volume":"176","author":"Pilgrim","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2021.101475_bib0050","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ni.3158","article-title":"Antibody responses to envelope glycoproteins in HIV-1 infection","volume":"16","author":"Burton","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2021.101475_bib0055","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2021.101475_bib0060","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.immuni.2019.04.014","article-title":"Broad and potent neutralizing antibodies recognize the silent face of the HIV envelope","volume":"50","author":"Schoofs","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2021.101475_bib0065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/aid.1994.10.359","article-title":"Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization","volume":"10","author":"Buchacher","year":"1994","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.smim.2021.101475_bib0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.smim.2021.101475_bib0075","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.smim.2021.101475_bib0080","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.smim.2021.101475_bib0085","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.smim.2021.101475_bib0090","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0095","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2021.101475_bib0100","doi-asserted-by":"crossref","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.smim.2021.101475_bib0105","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0110","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"Sok","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.smim.2021.101475_bib0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies","volume":"509","author":"Doria-Rose","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0120","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0125","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","article-title":"Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity","volume":"165","author":"Huang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.smim.2021.101475_bib0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.smim.2021.101475_bib0135","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.4049\/jimmunol.149.5.1779","article-title":"Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion","volume":"149","author":"Burkly","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2021.101475_bib0140","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/JVI.75.2.579-588.2001","article-title":"Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140","volume":"75","author":"Trkola","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0145","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008064","article-title":"IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody","volume":"15","author":"Richardson","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.smim.2021.101475_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008083","article-title":"Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies","volume":"16","author":"Chu","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.smim.2021.101475_bib0160","doi-asserted-by":"crossref","first-page":"F5","DOI":"10.1097\/QAD.0000000000001857","article-title":"Anti-HIV IgM protects against mucosal SHIV transmission","volume":"32","author":"Gong","year":"2018","journal-title":"Aids"},{"key":"10.1016\/j.smim.2021.101475_bib0165","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res."},{"key":"10.1016\/j.smim.2021.101475_bib0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.imlet.2009.06.003","article-title":"IgM in microbial infections: taken for granted?","volume":"125","author":"Racine","year":"2009","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.smim.2021.101475_bib0175","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1097\/QAD.0b013e328359b99b","article-title":"Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples","volume":"26","author":"Choi","year":"2012","journal-title":"Aids"},{"key":"10.1016\/j.smim.2021.101475_bib0180","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/QAD.0b013e3282f56b64","article-title":"HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers","volume":"22","author":"Hirbod","year":"2008","journal-title":"Aids"},{"key":"10.1016\/j.smim.2021.101475_bib0185","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0b013e328360eac6","article-title":"Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission","volume":"27","author":"Watkins","year":"2013","journal-title":"Aids"},{"key":"10.1016\/j.smim.2021.101475_bib0190","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.chom.2020.03.024","article-title":"VSV-displayed HIV-1 envelope identifies broadly neutralizing antibodies class-switched to IgG and IgA","volume":"27","author":"Jia","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.smim.2021.101475_bib0195","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/eci.12716","article-title":"Immunoglobulin A: magic bullet or Trojan horse?","volume":"47","author":"Heineke","year":"2017","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.smim.2021.101475_bib0200","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3389\/fimmu.2020.01141","article-title":"Antibody-dependent cellular phagocytosis of HIV-1-infected cells Is efficiently triggered by IgA targeting HIV-1 envelope subunit gp41","volume":"11","author":"Duchemin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2021.101475_bib0205","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0210","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.smim.2021.101475_bib0215","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jsb.2016.02.001","article-title":"Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcgammaRIIIa","volume":"194","author":"Ahmed","year":"2016","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.smim.2021.101475_bib0220","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1073\/pnas.1702173114","article-title":"Modulating IgG effector function by Fc glycan engineering","volume":"114","author":"Li","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.smim.2021.101475_bib0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molimm.2016.03.002","article-title":"Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies","volume":"73","author":"Thomann","year":"2016","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.smim.2021.101475_bib0230","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","article-title":"The \u201cless-is-more\u201d in therapeutic antibodies: afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"10","author":"Pereira","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.smim.2021.101475_bib0235","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1097\/QAD.0000000000000444","article-title":"Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function","volume":"28","author":"Chung","year":"2014","journal-title":"Aids"},{"key":"10.1016\/j.smim.2021.101475_bib0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4161\/mabs.20996","article-title":"Marketing approval of mogamulizumab: a triumph for glyco-engineering","volume":"4","author":"Beck","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.smim.2021.101475_bib0245","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cell.2016.04.050","article-title":"Bispecific anti-HIV-1 antibodies with enhanced breadth and potency","volume":"165","author":"Bournazos","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.smim.2021.101475_bib0250","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03080-19","article-title":"A bispecific antibody that simultaneously recognizes the V2- and V3-glycan epitopes of the HIV-1 envelope glycoprotein is broader and more potent than its parental antibodies","volume":"11","author":"Davis-Gardner","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.smim.2021.101475_bib0255","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00384-18","article-title":"Targeting the HIV-1 spike and coreceptor with Bi- and trispecific antibodies for single-component broad inhibition of entry","volume":"92","author":"Khan","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0260","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/COH.0000000000000440","article-title":"Humanized mouse models to study pathophysiology and treatment of HIV infection","volume":"13","author":"Masse-Ranson","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.smim.2021.101475_bib0265","first-page":"E3413","article-title":"Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques","volume":"113","author":"Li","year":"2016","journal-title":"PNAS"},{"key":"10.1016\/j.smim.2021.101475_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005431","article-title":"Production of mucosally transmissible SHIV challenge stocks from HIV-1 circulating recombinant form 01_AE env sequences","volume":"12","author":"Tartaglia","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.smim.2021.101475_bib0275","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/JVI.03279-14","article-title":"Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks","volume":"89","author":"Chang","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0280","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1128\/JVI.75.17.8340-8347.2001","article-title":"Antibody protects macaques against vaginal challenge with a pathogenic R5 simian\/human immunodeficiency virus at serum levels giving complete neutralization in vitro","volume":"75","author":"Parren","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0285","doi-asserted-by":"crossref","first-page":"10447","DOI":"10.1128\/JVI.00049-13","article-title":"Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques","volume":"87","author":"Jaworski","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0290","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nm.1974","article-title":"Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques","volume":"15","author":"Hessell","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000433","article-title":"Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers","volume":"5","author":"Hessell","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.smim.2021.101475_bib0300","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"Mascola","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0305","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1084\/jem.20132494","article-title":"Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques","volume":"211","author":"Shingai","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0310","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008992","article-title":"Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor","volume":"6","author":"Pegu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0315","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/72309","article-title":"Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection","volume":"6","author":"Baba","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0320","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.smim.2021.101475_bib0325","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1483","article-title":"Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection","volume":"9","author":"Parsons","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0330","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature17677","article-title":"A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges","volume":"533","author":"Gautam","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0335","article-title":"Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge","volume":"9","author":"Julg","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0340","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/QAD.0000000000000298","article-title":"Estimating per-act HIV transmission risk: a systematic review","volume":"28","author":"Patel","year":"2014","journal-title":"Aids"},{"key":"10.1016\/j.smim.2021.101475_bib0345","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","article-title":"A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge","volume":"26","author":"Pegu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.smim.2021.101475_bib0350","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01187-17","article-title":"Protective efficacy of broadly neutralizing antibodies with incomplete neutralization activity against simian-human immunodeficiency virus in rhesus monkeys","volume":"91","author":"Julg","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0355","doi-asserted-by":"crossref","DOI":"10.1126\/science.aag0491","article-title":"Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus","author":"Liu","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.smim.2021.101475_bib0360","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0365","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1172\/JCI122466","article-title":"Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques","volume":"129","author":"Parsons","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2021.101475_bib0370","article-title":"Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0375","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm1297-1389","article-title":"Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1","volume":"3","author":"Gauduin","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0380","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/infdis\/jiw203","article-title":"Protection of humanized mice from repeated intravaginal HIV challenge by passive immunization: a model for studying the efficacy of neutralizing antibodies in vivo","volume":"214","author":"Deruaz","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2021.101475_bib0385","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s00705-016-2942-4","article-title":"VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice","volume":"161","author":"Sun","year":"2016","journal-title":"Arch. Virol"},{"key":"10.1016\/j.smim.2021.101475_bib0390","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0395","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission","volume":"20","author":"Balazs","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0400","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1089\/aid.2018.0114","article-title":"Short communication: protective efficacy of broadly neutralizing antibody PGDM1400 against HIV-1 challenge in humanized mice","volume":"34","author":"van der Velden","year":"2018","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.smim.2021.101475_bib0405","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1172\/JCI96764","article-title":"Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice","volume":"128","author":"Wu","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2021.101475_bib0410","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00937-17","article-title":"Potent in vivo NK cell-mediated elimination of HIV-1-infected cells mobilized by a gp120-bispecific and hexavalent broadly neutralizing fusion protein","volume":"91","author":"Bardhi","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0415","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.smim.2021.101475_bib0420","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.smim.2021.101475_bib0425","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02051-18","article-title":"Establishment of A novel humanized mouse model to investigate in vivo activation and depletion of patient-derived HIV latent reservoirs","author":"Flerin","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0430","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1074-7613(00)80043-6","article-title":"Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo","volume":"10","author":"Poignard","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2021.101475_bib0435","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.virol.2014.05.036","article-title":"Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice","volume":"462\u2013463","author":"Stoddart","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.smim.2021.101475_bib0440","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0445","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1315295110","article-title":"HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice","volume":"110","author":"Horwitz","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.smim.2021.101475_bib0450","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0455","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1084\/jem.20141050","article-title":"Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants","volume":"211","author":"Klein","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0460","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2144","article-title":"Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller","volume":"9","author":"Freund","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0465","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody","volume":"180","author":"Schommers","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.smim.2021.101475_bib0470","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0475","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"Shingai","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0480","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00498-17","article-title":"Virological control by the CD4-binding site antibody N6 in simian-human immunodeficiency virus-infected rhesus monkeys","volume":"91","author":"Julg","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0485","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/mi.2013.23","article-title":"Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques","volume":"7","author":"Moog","year":"2014","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.smim.2021.101475_bib0490","doi-asserted-by":"crossref","first-page":"6906","DOI":"10.1128\/JVI.00326-11","article-title":"Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys","volume":"85","author":"Sun","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0495","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1128\/JVI.00313-11","article-title":"Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses","volume":"85","author":"Asmal","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0500","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/ni.3152","article-title":"HIV reservoirs as obstacles and opportunities for an HIV cure","volume":"16","author":"Chun","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2021.101475_bib0505","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.smim.2021.101475_bib0510","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0515","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0520","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0525","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1084\/jem.20180936","article-title":"Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117","volume":"215","author":"Cohen","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0530","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.smim.2021.101475_bib0535","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0540","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0545","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Crowell","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.smim.2021.101475_bib0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.smim.2021.101475_bib0555","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.smim.2021.101475_bib0560","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0565","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1128\/JVI.03246-15","article-title":"Optimization of the solubility of HIV-1-neutralizing antibody 10E8 through somatic variation and structure-based design","volume":"90","author":"Kwon","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2021.101475_bib0570","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","article-title":"Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression","volume":"50","author":"Martinez-Navio","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2021.101475_bib0575","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.smim.2021.101475_bib0580","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","article-title":"Vaccines and broadly neutralizing antibodies for HIV-1 prevention","volume":"38","author":"Stephenson","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.smim.2021.101475_bib0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection","volume":"12","author":"Wagh","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.smim.2021.101475_bib0590","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2021.101475_bib0595","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101475_bib0600","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1172\/JCI134815","article-title":"HIV persists throughout deep tissues with repopulation from multiple anatomical sources","volume":"130","author":"Chaillon","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2021.101475_bib0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181680","article-title":"Probing the compartmentalization of HIV-1 in the central nervous system through its neutralization properties","volume":"12","author":"Stefic","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.smim.2021.101475_bib0610","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005789","article-title":"Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time","volume":"13","author":"Hake","year":"2017","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.smim.2021.101475_bib0615","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130153","article-title":"Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir","volume":"4","author":"Yu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.smim.2021.101475_bib0620","doi-asserted-by":"crossref","first-page":"14696","DOI":"10.1038\/s41598-019-50635-w","article-title":"Accurate prediction for antibody resistance of clinical HIV-1 isolates","volume":"9","author":"Rawi","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532321000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532321000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:20:26Z","timestamp":1760916026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532321000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":124,"alternative-id":["S1044532321000063"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2021.101475","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Broadly neutralizing antibodies for HIV-1 prevention and therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2021.101475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101475"}}